Photo of David E. Fisher,  MD, PhD

David E. Fisher, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 643-5428

David E. Fisher, MD, PhD

Massachusetts General Hospital


  • Edward Wigglesworth Professor of Dermatology, Biological Chemistry and Molecular Pharmacology, Harvard Medical School
  • Edward Wigglesworth Professor of Dermatology, Dermatology, Harvard Medical School
  • Director, Melanoma Program , Cancer Center, Massachusetts General Hospital
  • Chief, Dermatology, Massachusetts General Hospital



  • Member, Center Scientific Council

Research Abstract

The Fisher laboratory focuses on mechanistic studies which underlie the biology and pathophysiology of skin and melanoma. Research studies range from molecular analyses of pigment cell biology to risk factors responsible for the formation of melanoma and other skin cancers. The laboratory utilizes deep molecular tools to understand how genes are regulated, how they contribute to cancer formation, and how they may be successfully targeted by drugs in order to improve disease treatments or to prevent disease formation altogether. Several areas of particular focus include 1) the study of redhair, fair skinned pigmentation and the manner in which such individuals are at increased risk for skin cancer; 2) identification and analysis of oncogenes which control melanoma cell survival; 3) discovery of new drugs that affect pigmentation, melanoma survival, and other skin-related effects; and 4) examination of the ways in which a gene called MITF plays a master-regulatory role in specifying the development of pigment-producing cells in the body.


Powered by Harvard Catalyst
  • Osseiran S, Roider EM, Wang H, Suita Y, Murphy M, Fisher DE, Evans CL. Non-Euclidean phasor analysis for quantification of oxidative stress in ex vivo human skin exposed to sun filters using fluorescence lifetime imaging microscopy. J Biomed Opt 2017; 22:1-10. PubMed
  • Heppt MV, Wang JX, Hristova DM, Wei Z, Li L, Evans B, Beqiri M, Zaman S, Zhang J, Irmler M, Berking C, Besch R, Beckers J, Rauscher FJ, Sturm RA, Fisher DE, Herlyn M, Fukunaga-Kalabis M. MSX1-induced neural crest-like reprogramming promotes melanoma progression. J Invest Dermatol 2017. PubMed
  • Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher DE. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res 2017. PubMed
  • Tateishi K, Higuchi F, Miller JJ, Koerner MVA, Lelic N, Shankar GM, Tanaka S, Fisher DE, Batchelor TT, Iafrate AJ, Wakimoto H, Chi AS, Cahill DP. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD(+) Depletion-Mediated Cytotoxicity. Cancer Res 2017. PubMed
  • Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, Lo J, Fisher DE, Miao D, Van Allen E, Root DE, Sharpe AH, Doench JG, Haining WN. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 2017; 547:413-418. PubMed
  • Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D, Shah K. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci U S A 2017; 114:E6157-E6165. PubMed
  • Mujahid N, Liang Y, Murakami R, Choi HG, Dobry AS, Wang J, Suita Y, Weng QY, Allouche J, Kemeny LV, Hermann AL, Roider EM, Gray NS, Fisher DE. A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. Cell Rep 2017; 19:2177-2184. PubMed
  • Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer 2017; 123:2143-2153. PubMed
  • Salma N, Song JS, Kawakami A, Devi SP, Khaled M, Cacicedo JM, Fisher DE. Tfe3 and Tfeb transcriptionally regulate Pparγ2 expression in adipocytes and mediate adiponectin and glucose levels in mice. Mol Cell Biol 2017. PubMed
  • Kawakami A, Fisher DE. The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab Invest 2017. PubMed
  • Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag 2017; 4:13-37. PubMed
  • Alves CP, Yokoyama S, Goedert L, Pontes CL, Sousa JF, Fisher DE, Espreafico EM. MYO5A gene is a target of MITF in melanocytes. J Invest Dermatol 2016. PubMed
  • Lin WM, Fisher DE. Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. Annu Rev Pathol 2016. PubMed
  • Kawakami A, Fisher DE. Bioinformatic Analysis of Gene Expression for Melanoma Treatment. J Invest Dermatol 2016; 136:2342-2344. PubMed
  • Su MY, Fisher DE. Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Med. 2016; 13:e1002196. PubMed
  • Wang H, Osseiran S, Igras V, Nichols AJ, Roider EM, Pruessner J, Tsao H, Fisher DE, Evans CL. In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. Sci Rep 2016; 6:37986. PubMed
  • Ibrahim N, Buchbinder EI, Granter SR, Rodig SJ, Giobbie-Hurder A, Becerra C, Tsiaras A, Gjini E, Fisher DE, Hodi FS. A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med 2016; 5:3041-3050. PubMed
  • Herzberg B, Fisher DE. Metastatic melanoma and immunotherapy. Clin Immunol 2016. PubMed
  • Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res 2016. PubMed
  • Roider EM, Fisher DE. Red Hair, Light Skin, and UV-Independent Risk for Melanoma Development in Humans. JAMA Dermatol 2016. PubMed
  • Xia Y, Li Y, Westover KD, Sun J, Chen H, Zhang J, Fisher DE. Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin. PLoS ONE 2016; 11:e0155217. PubMed
  • Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JR, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MV, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell 2015; 28:773-84. PubMed
  • Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer 2015; 15:747-56. PubMed
  • Salma N, Song JS, Arany Z, Fisher DE. Transcription Factor Tfe3 Directly Regulates Pgc-1alpha in Muscle. J Cell Physiol 2015. PubMed
  • Lu FK, Basu S, Igras V, Hoang MP, Ji M, Fu D, Holtom GR, Neel VA, Freudiger CW, Fisher DE, Xie XS. Label-free DNA imaging in vivo with stimulated Raman scattering microscopy. Proc Natl Acad Sci U S A 2015; 112:11624-9. PubMed
  • Lo JA, Fisher DE, Flaherty KT. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. JAMA Oncol 2015. PubMed
  • Liu XS, Genet MD, Haines JE, Mehanna EK, Wu S, Chen HI, Chen Y, Qureshi AA, Han J, Chen X, Fisher DE, Pandolfi PP, Yuan ZM. ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. Mol Cancer Res 2015. PubMed
  • Yoon KW, Byun S, Kwon E, Hwang SY, Chu K, Hiraki M, Jo SH, Weins A, Hakroush S, Cebulla A, Sykes DB, Greka A, Mundel P, Fisher DE, Mandinova A, Lee SW. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science 2015; 349:1261669. PubMed
  • Goldberg JM, Fisher DE, Demetri GD, Neuberg D, Allsop SA, Fonseca C, Nakazaki Y, Nemer D, Raut CP, George S, Morgan JA, Wagner AJ, Freeman GJ, Ritz J, Lezcano C, Mihm M, Canning C, Hodi FS, Dranoff G. Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res 2015. PubMed
  • Lauss M, Haq R, Cirenajwis H, Phung B, Harbst K, Staaf J, Rosengren F, Holm K, Aine M, Jirström K, Borg Å, Busch C, Geisler J, Lønning PE, Ringnér M, Howlin J, Fisher DE, Jönsson G. Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. J Invest Dermatol 2015. PubMed
  • Zheng B, Fisher DE. Metabolic vulnerability in melanoma: a ME2 (me too) story. J Invest Dermatol 2015; 135:657-9. PubMed
  • Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, Fisher DE. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS ONE 2015; 10:e0140310. PubMed
  • Dadras SS, Lin RJ, Razavi G, Kawakami A, Du J, Feige E, Milner DA, Loda MF, Granter SR, Detmar M, Widlund HR, Horstmann MA, Fisher DE. A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression. Am J Pathol 2014; 185:252-65. PubMed
  • Hsiao JJ, Fisher DE. The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Arch Biochem Biophys 2014. PubMed
  • Lee JH, Fisher DE. Melanocyte stem cells as potential therapeutics in skin disorders. Expert Opin Biol Ther 2014; 14:1569-79. PubMed
  • Choi YS, Fisher DE. UV and melanoma: the TP53 link. Cell Res 2014; 24:1157-8. PubMed
  • Chen H, Weng QY, Fisher DE. UV signaling pathways within the skin. J Invest Dermatol 2014. PubMed
  • Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. 2014. PubMed
  • Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014. PubMed
  • Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res 2014. PubMed
  • Sullivan RJ, Fisher DE. Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am 2014; 28:437-53. PubMed
  • Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA. Isolation and molecular characterization of circulating melanoma cells. Cell Rep 2014. PubMed
  • Haq R, Fisher DE, Widlund HR. Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res 2014. PubMed
  • Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. 2014. PubMed
  • Lee JH, Chen H, Kolev V, Aull KH, Jung I, Wang J, Miyamoto S, Hosoi J, Mandinova A, Fisher DE. High-throughput, high-content screening for novel pigmentation regulators using a keratinocyte/melanocyte co-culture system. Exp Dermatol 2014; 23:125-9. PubMed
  • Dreze M, Calkins AS, Gálicza J, Echelman DJ, Schnorenberg MR, Fell GL, Iwai S, Fisher DE, Szüts D, Iglehart JD, Lazaro JB. Monitoring repair of UV-induced 6-4-photoproducts with a purified DDB2 protein complex. PLoS ONE 2014; 9:e85896. PubMed
  • Levine D, Fisher DE. Current status of diagnostic and prognostic markers in melanoma. Methods Mol Biol 2013; 1102:177-97. PubMed
  • Roider EM, Fisher DE. The impact of MITF on melanoma development: news from bench and bedside. J Invest Dermatol 2013; 134:16-7. PubMed
  • Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS ONE 2014; 9:e101286. PubMed
  • Alves CP, Moraes MH, Sousa JF, Pontes CL, Ramão A, Yokoyama S, Trindade DM, Fisher DE, Espreafico EM. Myosin-Va contributes to manifestation of malignant-related properties in melanoma cells. J Invest Dermatol 2013. PubMed
  • Praetorius C, Grill C, Stacey SN, Metcalf AM, Gorkin DU, Robinson KC, Van Otterloo E, Kim RS, Bergsteinsdottir K, Ogmundsdottir MH, Magnusdottir E, Mishra PJ, Davis SR, Guo T, Zaidi MR, Helgason AS, Sigurdsson MI, Meltzer PS, Merlino G, Petit V, Larue L, Loftus SK, Adams DR, Sobhiafshar U, Emre NC, Pavan WJ, Cornell R, Smith AG, McCallion AS, Fisher DE, Stefansson K, Sturm RA, Steingrimsson E. A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell 2013; 155:1022-33. PubMed
  • Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2013; 2:e26615. PubMed
  • Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013; 31:3182-90. PubMed
  • Haq R, Fisher DE. Improving apoptotic responses to targeted therapy. 2013; 4:1331. PubMed
  • Morgan AM, Lo J, Fisher DE. How does pheomelanin synthesis contribute to melanomagenesis?: Two distinct mechanisms could explain the carcinogenicity of pheomelanin synthesis. Bioessays 2013. PubMed
  • Fisher DE, Geller AC. Disproportionate burden of melanoma mortality in young U.S. men: the possible role of biology and behavior. JAMA Dermatol 2013; 149:903-4. PubMed
  • Liu S, Wang J, Su Y, Guerrero C, Zeng Y, Mitra D, Brooks PJ, Fisher DE, Song H, Wang Y. Quantitative assessment of Tet-induced oxidation products of 5-methylcytosine in cellular and tissue DNA. Nucleic Acids Res 2013. PubMed
  • Haq R, Fisher DE. Targeting melanoma by small molecules: challenges ahead. Pigment Cell Melanoma Res 2013. PubMed
  • Korman JB, Fisher DE. Developing melanoma therapeutics: overview and update. 2013; 5:257-71. PubMed
  • Fink EC, Fisher DE. BRAF and MC1R in melanoma: different in head and neck tumors? J Invest Dermatol 2013; 133:878-80. PubMed
  • Balk SJ, Fisher DE, Geller AC. Teens and indoor tanning: a cancer prevention opportunity for pediatricians. Pediatrics 2013; 131:772-85. PubMed
  • Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 2013; 23:302-15. PubMed
  • Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 2013; 110:4321-6. PubMed
  • Balk SJ, Fisher DE, Geller AC. Stronger laws are needed to protect teens from indoor tanning. Pediatrics 2013; 131:586-8. PubMed
  • Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-31. PubMed
  • Shoag J, Haq R, Zhang M, Liu L, Rowe GC, Jiang A, Koulisis N, Farrel C, Amos CI, Wei Q, Lee JE, Zhang J, Kupper TS, Qureshi AA, Cui R, Han J, Fisher DE, Arany Z. PGC-1 coactivators regulate MITF and the tanning response. Mol Cell 2013; 49:145-57. PubMed
  • Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012; 491:449-53. PubMed
  • Jalili A, Wagner C, Pashenkov M, Pathria G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G, Fisher DE, Ramaswamy S, Wagner SN. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. Journal of the National Cancer Institute 2012; 104:1673-9. PubMed
  • Geller AC, Balk SJ, Fisher DE. Stemming the tanning bed epidemic: time for action. J Natl Compr Canc Netw 2012; 10:1311-4. PubMed
  • Anghel SI, Correa-Rocha R, Correa-Rochal R, Budinska E, Boligan KF, Boliganl KF, Abraham S, Colombetti S, Fontao L, Mariotti A, Rimoldi D, Ghanem GE, Fisher DE, Lévy F, Delorenzi M, Piguet V. Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF. Pigment Cell Melanoma Res 2012; 25:482-7. PubMed
  • Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012; 26:1131-55. PubMed
  • Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012; 12:349-61. PubMed
  • Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg D, Brown JR. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011. PubMed
  • Mitra D, Robinson KC, Fisher DE. Melanoma and viagra: an unexpected connection. Pigment Cell Melanoma Res 2011; 24:16-8. PubMed
  • Levy C, Fisher DE. Dual roles of lineage restricted transcription factors: the case of MITF in melanocytes. Transcr 2012; 2:19-22. PubMed
  • D'Orazio J, Fisher DE. Central role for cAMP signaling in pigmentation and UV resistance. Cell Cycle 2011; 10:8-9. PubMed
  • Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, Chen PH, Li S, Fletcher AL, Yokoyama S, Scott KL, Garraway LA, Song JS, Granter SR, Turley SJ, Fisher DE, Novina CD. Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma. Mol Cell 2010; 40:841-849. PubMed
  • Liu JJ, Fisher DE. Lighting a path to pigmentation: mechanisms of MITF induction by UV. Pigment Cell Melanoma Res 2010; 23:741-5. PubMed
  • Khaled M, Levy C, Fisher DE. Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes Dev 2010; 24:2276-81. PubMed
  • Fisher DE, James WD. Indoor tanning--science, behavior, and policy. N Engl J Med 2010; 363:901-3. PubMed
  • Garibyan L, Fisher DE. How sunlight causes melanoma. Curr Oncol Rep 2010; 12:319-26. PubMed
  • Weinstock MA, Fisher DE. Indoor ultraviolet tanning: what the data do and do not show regarding risk of melanoma and keratinocyte malignancies. J Natl Compr Canc Netw 2010; 8:867-73. PubMed
  • Park JM, Fisher DE. Testimony from the bedside: from Coley's toxins to targeted immunotherapy. Cancer Cell 2010; 18:9-10. PubMed
  • Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213-9. PubMed
  • Weinberg R, Fisher DE, Rich J. Dynamic and transient cancer stem cells nurture melanoma. Nat Med 2010; 16:758. PubMed
  • Levy C, Khaled M, Robinson KC, Veguilla RA, Chen PH, Yokoyama S, Makino E, Lu J, Larue L, Beermann F, Chin L, Bosenberg M, Song JS, Fisher DE. Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell 2010; 141:994-1005. PubMed
  • Stewart RA, Sanda T, Widlund HR, Zhu S, Swanson KD, Hurley AD, Bentires-Alj M, Fisher DE, Kontaridis MI, Look AT, Neel BG. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell 2010; 18:750-62. PubMed
  • Gordon PM, Fisher DE. Role for the pro-apoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT dependent gastrointestinal stromal tumor cell line. J Biol Chem 2010; 285:14109-14. PubMed
  • Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, Winckler W, Fisher DE, Getz G, Meyerson M, Jaffe DB, Gabriel SB, Lander ES, Dummer R, Gnirke A, Nusbaum C, Garraway LA. Integrative analysis of the melanoma transcriptome. Genome Res 2010; 20:413-27. PubMed
  • Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE, Garraway LA. An oncogenic role for ETV1 in melanoma. Cancer Res 2010; 70:2075-84. PubMed
  • Nishimura EK, Suzuki M, Igras V, Du J, Lonning S, Miyachi Y, Roes J, Beermann F, Fisher DE. Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell 2010; 6:130-40. PubMed
  • Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res 2010; 70:639-45. PubMed
  • Yokoyama S, Salma N, Fisher DE. MITF pathway mutations in melanoma. Pigment Cell Melanoma Res 2009; 22:376-7. PubMed
  • Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009; 459:1085-90. PubMed
  • Zhao X,Graves C,Ames SJ,Fisher DE,Spanjaard RA. Mechanism of Regulation and Suppression of Melanoma Invasiveness by Novel Retinoic Acid Receptor-{gamma} Target Gene Carbohydrate Sulfotransferase 10. Cancer Res 2009; 69:5218-25. PubMed
  • Mitra D,Fisher DE. Transcriptional regulation in melanoma. Hematol Oncol Clin North Am 2009; 23:447-65, viii. PubMed
  • Fisher DE. Advances in melanoma. Preface. Hematol Oncol Clin North Am 2009; 23:xiii-xiv. PubMed
  • Schulman JM, Fisher DE. Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr Opin Oncol 2009; 21:144-9. PubMed
  • Robinson KC,Fisher DE. Specification and loss of melanocyte stem cells. Semin Cell Dev Biol 2009; 20:111-6. PubMed
  • Jiang X,Zhou J,Yuen NK,Corless CL,Heinrich MC,Fletcher JA,Demetri GD,Widlund HR,Fisher DE,Hodi FS. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008; 14:7726-32. PubMed
  • Hodi FS,Fisher DE. Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat Clin Pract Oncol 2008; 5:696-7. PubMed
  • Ozsolak F,Poling LL,Wang Z,Liu H,Liu XS,Roeder RG,Zhang X,Song JS,Fisher DE. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008; 22:3172-83. PubMed
  • Osawa M,Fisher DE. Notch and melanocytes: diverse outcomes from a single signal. J Invest Dermatol 2008; 128:2571-4. PubMed
  • Tran TT,Schulman J,Fisher DE. UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell Melanoma Res 2008; 21:509-16. PubMed
  • Yokoyama S,Feige E,Poling LL,Levy C,Widlund HR,Khaled M,Kung AL,Fisher DE. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 2008; 21:457-63. PubMed
  • Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma 2008; 49:902-9. PubMed
  • Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26:2046-51. PubMed
  • Sato-Jin K, Nishimura EK, Akasaka E, Huber W, Nakano H, Miller A, Du J, Wu M, Hanada K, Sawamura D, Fisher DE, Imokawa G. Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders. FASEB J 2007; 22:1155-68. PubMed
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14:418-25. PubMed
  • Fisher DE, Medrano EE, McMahon M, Soengas MS, Schuchter L, Wolchok JD, Merlino G. Meeting Report: Fourth International Congress of the Society for Melanoma Research. Pigment Cell Melanoma Res 2008; 21:15-26. PubMed
  • Kawakami A, Sakane F, Imai S, Yasuda S, Kai M, Kanoh H, Jin HY, Hirosaki K, Yamashita T, Fisher DE, Jimbow K. Rab7 regulates maturation of melanosomal matrix protein gp100/Pmel17/Silv. J Invest Dermatol 2007; 128:143-50. PubMed
  • Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57:1151-7. PubMed
  • Widlund HR, Fisher DE. Potent p53-independent tumor suppressor activity of ARF in melanoma-genesis. Pigment Cell Res 2007; 20:339-40. PubMed
  • Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13:1057-65. PubMed
  • Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 2007; 13:838-43. PubMed
  • Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D'Orazio J, Fung CY, Schanbacher CF, Granter SR, Fisher DE. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007; 128:853-64. PubMed
  • Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007; 445:843-50. PubMed
  • Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, La. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007; 67:919-29. PubMed
  • Ozsolak F, Song JS, Liu XS, Fisher DE. High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol 2007; 25:244-8. PubMed
  • Chang EJ, Kim HJ, Ha J, Kim HJ, Ryu J, Park KH, Kim UH, Lee ZH, Kim HM, Fisher DE, Kim HH. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci 2006; 120:166-76. PubMed
  • D'Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, Igras V, Kunisada T, Granter SR, Nishimura EK, Ito S, Fisher DE. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 2006; 443:340-4. PubMed
  • Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006; 12:406-14. PubMed
  • Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006; 20:2149-82. PubMed
  • Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, Du J, Fletcher JA, Denny CT, Lessnick SL, Linehan WM, Kung AL, Fisher DE. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 2006; 9:473-84. PubMed
  • McGill GG, Haq R, Nishimura EK, Fisher DE. c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 2006; 281:10365-73. PubMed
  • Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436:117-22. PubMed
  • Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD, Aster JC, Granter SR, Look AT, Lee C, Fisher DE, Zon LI. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 2005; 15:249-54. PubMed
  • Nishimura EK, Granter SR, Fisher DE. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 2004; 307:720-4. PubMed
  • Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR. "Lineage Addiction" in Human Cancer: Lessons from Integrated Genomics. Cold Spring Harb Symp Quant Biol 2006; 70:25-34. PubMed
  • Granter SR, Weilbaecher KN, Quigley C, Fisher DE. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol 2002; 10:47-51. PubMed